Search

Your search keyword '"Venkat, Puja S."' showing total 19 results
Start Over Author "Venkat, Puja S."
19 results on '"Venkat, Puja S."'

2. Effectiveness of Single-Fraction, Low-Dose, Bilateral Whole Lung Radiation Therapy for Diffuse Alveolar Hemorrhage Secondary to Extramedullary Hematopoiesis: A case report and review of the literature

Author

Neilsen, Beth K., primary, Sleightholm, Richard L., additional, Gower, Arjan, additional, Tsai, Steven C., additional, Schiller, Gary J., additional, Oliai, Caspian, additional, Lee, Alan, additional, Raldow, Ann, additional, Tenn, Stephen, additional, and Venkat, Puja S., additional

Published
2024
Full Text
View/download PDF

9. Sanguinarine exhibits potent efficacy against cervical cancer cells through inhibiting the STAT3 pathway in vitro and in vivo

Author

Zhang,Huijuan, Zhang,Jing, Venkat,Puja S, Gu,Chenglei, and Meng,Yuanguang

Subjects
STAT3, Cancer Management and Research, cervical cancer, apoptosis, ROS, sanguinarine, Original Research
Abstract

Huijuan Zhang,*,1 Jing Zhang,*,2 Puja S Venkat,3 Chenglei Gu,1 Yuanguang Meng11Department of Gynecology and Obstetrics, The First Medical Center, The General Hospital of the People’s Liberation Army, Beijing, People’s Republic of China; 2Department of Gynecology, Guangdong Hydropower Hospital, Guangdong, People’s Republic of China; 3Radiation Oncology, David Geffen School of Medicine, University of California, Los Angeles, CA, USA*These authors contributed equally to this workBackground: Cervical cancer is the third most common malignancy among female cancer patients worldwide. Signal transducer and activator of transcription 3 (STAT3) is a transcription factor which regulates a variety of cancer cellular physiological activities including cervical cancer. Sanguinarine (SNG) is a natural plant-derived benzophenanthridine alkaloid that possesses antitumor activities in several cancer cells. However, its anticancer effect on human cervical cancer cells and the underlying mechanisms have not been fully defined.Methods: In this study, the inhibitory effect of SNG on the proliferation and growth of HeLa cell was detected by MTT assay. Next, cell cycle and apoptosis of HeLa cells was analyzed using Annexin-V/PI double staining and flow cytometry. Then, we measured intracellular ROS generation induced by SNG in HeLa cells by DCFH-DA (10 μM) staining, and the expression level of p-STAT3 and STAT3 was detected by Western blot. Finally, in order to study the effect of SNG on tumor growth in vivo, athymic nude mice were used in the vivo experiments.Result: This study showed that SNG dose-dependently decreased the tumor cell proliferation and induced a marked increase in cell apoptosis in HeLa cells. Western blot analysis results revealed that SNG-induced antitumor effect might be mediated by STAT3 inhibition. SNG increased the expression of the proapoptotic protein Bax and reduced the expression of the antiapoptotic protein Bcl-2. We further found that SNG dose-dependently increased ROS level in Hela cells. Moreover, pretreatment with N-acetyl-l-cysteine, a scavenger of ROS, almost reversed the SNG-induced anticancer effect. In addition, SNG inhibited human cervical cancer xenograft growth without exhibiting toxicity in vivo.Conclusion: Our findings highlight STAT3 as a promising therapeutic target. We also demonstrate that SNG is a novel anticancer drug for the treatment of cervical cancer.Keywords: sanguinarine, STAT3, ROS, apoptosis, cervical cancer

Published
2019

10. Contemporary Radiation Treatment of Prostate Cancer in Africa: A Ghanaian Experience

Author

Asamoah, Francis A., primary, Yarney, Joel, additional, Awasthi, Shivanshu, additional, Vanderpuye, Verna, additional, Venkat, Puja S., additional, Fink, Angelina K., additional, Naghavi, Arash O., additional, Abrahams, Afua, additional, Mensah, James E., additional, Sasu, Evans, additional, Tagoe, Samuel N.A., additional, Johnstone, Peter A.S., additional, and Yamoah, Kosj, additional

Published
2018
Full Text
View/download PDF

11. The American Brachytherapy Society and the American Radium Society Appropriate Use Criteria Genitourinary Committee Endorse the American Society of Clinical Oncology/Cancer Care Ontario Guidelines

Author

Chang, Albert J., primary, McBride, Sean, additional, Keyes, Mira, additional, Chung, Hans T., additional, Davis, Brian J., additional, Cox, Brett W., additional, Crook, Juanita, additional, Demanes, David J., additional, Hsu, I. Chow, additional, Kamrava, Mitchell, additional, Krauss, Daniel J., additional, Morton, Gerard, additional, Orio III, Peter F., additional, Roach III, Mack, additional, Venkat, Puja S., additional, Vigneault, Eric, additional, and Zelefsky, Michael J., additional

Published
2018
Full Text
View/download PDF

12. Patient choice for high-volume center radiation impacts head and neck cancer outcome

Author

Naghavi, Arash O., primary, Echevarria, Michelle I., additional, Strom, Tobin J., additional, Abuodeh, Yazan A., additional, Venkat, Puja S., additional, Ahmed, Kamran A., additional, Demetriou, Stephanie, additional, Frakes, Jessica M., additional, Kim, Youngchul, additional, Kish, Julie A., additional, Russell, Jeffery S., additional, Otto, Kristen J., additional, Chung, Christine H., additional, Harrison, Louis B., additional, Trotti, Andy, additional, and Caudell, Jimmy J., additional

Published
2018
Full Text
View/download PDF

13. Impact of sarcopenia on outcomes of locally advanced esophageal cancer patients treated with neoadjuvant chemoradiation followed by surgery

Author

Murimwa, Gilbert Z., primary, Venkat, Puja S., additional, Jin, William, additional, Leuthold, Susan, additional, Latifi, Kujtim, additional, Almhanna, Khaldoun, additional, Pimiento, Jose M., additional, Fontaine, Jacques-Pierre, additional, Hoffe, Sarah E., additional, and Frakes, Jessica M., additional

Published
2017
Full Text
View/download PDF

15. Management of Oropharyngeal Cancer in the HPV Era

Author

Naghavi, Arash O., primary, Strom, Tobin J., additional, Ahmed, Kamran A., additional, Echevarria, Michelle I., additional, Abuodeh, Yazan A., additional, Venkat, Puja S., additional, Frakes, Jessica M., additional, Harrison, Louis B., additional, Trotti, Andy M., additional, and Caudell, Jimmy J., additional

Published
2016
Full Text
View/download PDF

17. Prognostic value of pre-treatment F-18-FDG PET-CT in patients with hepatocellular carcinoma undergoing radioembolization

Author

Abuodeh, Yazan, primary, Naghavi, Arash O, additional, Ahmed, Kamran A, additional, Venkat, Puja S, additional, Kim, Youngchul, additional, Kis, Bela, additional, Choi, Junsung, additional, Biebel, Benjamin, additional, Sweeney, Jennifer, additional, Anaya, Daniel A, additional, Kim, Richard, additional, Malafa, Mokenge, additional, Frakes, Jessica M, additional, Hoffe, Sarah E, additional, and El-Haddad, Ghassan, additional

Published
2016
Full Text
View/download PDF

18. Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.

Author

Venkat, Puja S., Hoffe, Sarah E., and Frakes, Jessica M.

Subjects
*LITERATURE reviews, *CANCER radiotherapy, *STEREOTACTIC radiotherapy, *RADIOTHERAPY complications, *LIVER diseases, *CLINICAL trials, *DISEASE risk factors, *HEPATOCELLULAR carcinoma, *LIVER tumors, *RADIOSURGERY
Abstract

The role of external beam radiation therapy for primary liver malignancies has historically been limited due to the risk of radiation-induced liver disease. However, with the advent of stereotactic body radiotherapy (SBRT), we are able to dose escalate while safely sparing critical nearby structures. This review explores the evidence surrounding the use of SBRT for the treatment of primary liver malignancies. A review of the literature was performed. This article discusses the challenges, efficacy, and safety of SBRT for primary liver malignancies in order to conceptualize its role within a multidisciplinary framework. Prospective phase I and II trials show local control rates at 1 to 2 years ranging from 65% to 100%. Overall survival at 1 to 2 years ranged from 48% to 77%. Grade >3 toxicity ranged from 0% to 36%. Total radiotherapy doses ranged from 24 to 60 Gy delivered in 1 to 6 fractions. The SBRT offers a noninvasive therapy for patients with limited treatment options and should be considered in a multidisciplinary setting for the management of unresectable, locally advanced primary liver malignancies. Prospective randomized trials are warranted to determine the efficacy and safety of SBRT compared to and in combination with other treatment modalities. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

19. Contemporary Radiation Treatment of Prostate Cancer in Africa: A Ghanaian Experience.

Author

Asamoah, Francis A., Yarney, Joel, Awasthi, Shivanshu, Vanderpuye, Verna, Venkat, Puja S., Fink, Angelina K., Naghavi, Arash O., Abrahams, Afua, Mensah, James E., Sasu, Evans, Tagoe, Samuel N.A., Johnstone, Peter A.S., and Yamoah, Kosj

Subjects
GLEASON grading system, PROSTATE-specific antigen, PROSTATE cancer, CANCER treatment, NUCLEAR medicine
Abstract

Purpose: Data on prostate cancer (PCa) treatment in Africa remains under-reported. We present a review of the management of PCa at the cancer center of the largest tertiary referral facility in Ghana, with emphasis on curative treatment. Methods: We retrospectively reviewed data on 1,074 patients seen at the National Center for Radiotherapy and Nuclear Medicine from 2003 to 2016. Patient and disease characteristics at presentation are presented using descriptive statistics. The χ2 and Fisher's exact tests and Mann-Whitney U test were used to analyze differences between categorical and continuous variables, respectively. Methods of survival analysis were used to evaluate the relative risk of biochemical disease-free survival (bDFS). Results: Seventy percent of the study population presented with localized disease. High-risk disease presentation accounted for 64.4% of these patients. Only 57.6% of patients with localized disease received curative radiotherapy. The 5-year overall survival for the curative cohort was 96% (interquartile range, 93% to 98%). The 5-year bDFS rates for low-, intermediate-, and high-risk groups were 95%, 70%, and 48%, respectively. Both Gleason score and pretreatment prostate-specific antigen were significant predictors for bDFS in multivariable analysis. Conclusion: We show that the majority of patients with PCa have locally advanced disease at the time of presentation for radiotherapy. bDFS was significantly better for low- and intermediate-risk than for high-risk disease. These data emphasize the dire need to re-evaluate screening and patient education of PCa in regions of the world with high incidence and mortality as well as the need for improved access to care and treatment delivery. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results